Following multiple doses, plasma levels are proportional to dose with no evidence of drug accumulation. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals ( Mefenamicacid is contraindicated in the following patients:Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Dietary administration of mefenamic acid at a dose of 181
Because
to seek immediate emergency help if these occur (seeAdvise patients to stop mefenamic acid immediately if
(0.6-times the MRHD on a mg/m² basis) from GD 6 to GD 18 did not result in any
Safety and effectiveness in pediatric patients below the
Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status.
Small studies in women treated with NSAIDs have also shown a reversible delay in ovulation.
Do not use NSAIDs for a condition for which it was not prescribed.
The capsule shell
In two 500-mg single oral dose studies, the mean extent of
diagnostic signs in detecting infections.Because serious GI bleeding, hepatotoxicity, and renal
Peak plasma levels are attained in 2–4 hours and its elimination half-life is approximately 2 hours. NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed
equivalent to the MRHD from 15 days prior to mating through to weaning resulted
mefenamic acid 1.6-times and 0.6-times the maximum recommended human dose
As with any NSAID, caution should be
Mefenamic acid cannot be expected to substitute for
Mefenamic Acid concentrations reached during therapy have produced in vivo effects.
decreased renal function, care should be taken in dose selection, and it may be
Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of Mefenamic Acid (see Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. made whether to discontinue nursing or to discontinue the drug, taking into
3-carboxymefenamic acid (Metabolite II) may occur.
In addition, … In animal studies, administration of prostaglandin synthesis inhibitors such as Mefenamic Acid, resulted in increased pre- and post-implantation loss.Pregnant rats administered 249 mg/kg of Mefenamic Acid (1.6-times the MRHD of 1500 mg/day on a mg/m Pregnant rabbits given 50 mg/kg of Mefenamic Acid (0.6-times the MRHD on a mg/m Dietary administration of Mefenamic Acid at a dose of 181 mg/kg (1.2-times the MRHD on a mg/m In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, decreased pup survival occurred and increased the incidence of stillbirth. acid was evaluated for the treatment of primary spasmodic dysmenorrhea. MI unless the benefits are expected to outweigh the risk of NSAIDs, including mefenamic acid, cause serious
In a multiple dose trial of normal adult subjects (n= 6) receiving 1-gram doses of Mefenamic Acid four times daily, steady-state concentrations of 20 mcg/mL were reached on the second day of administration, consistent with the short half-life.The effect of food on the rate and extent of absorption of Mefenamic Acid has not been studied. Revised: 2016The following adverse reactions are discussed in greater
The metabolites may accumulate in patients with renal or hepatic failure. Avoid use of NSAIDs, including mefenamic acid, in pregnant women
6; gelatin, NF; glycerol monooleate;
Patients received either Mefenamic Acid, 500 mg (2 capsules) as an initial dose of 250 mg every 6 hours, or placebo at onset of bleeding or of pain, whichever began first.